Werewolf Reports 30% Response Rate for WTX-124 Monotherapy in Melanoma Patients
- Clinical Data Highlight: WTX-124 demonstrated a 30% overall response rate as a monotherapy in post-ICI advanced melanoma patients, indicating its potential as a best-in-class tolerability drug.
- Efficacy Validation: Initial data from WTX-330 further confirmed its antitumor activity and favorable tolerability, building on the first-in-human trial, showcasing its prospects in challenging tumor types.
- Future Development Plans: The Phase 1/1b trial for WTX-124 is expected to complete in the first half of 2026, with additional data updates planned, potentially requiring further funding to initiate a registration trial.
- Strategic Partnership Opportunities: Werewolf is seeking strategic partners to advance the WTX-124 and WTX-330 INDUKINE programs, leveraging its unique INDUCER T cell engager platform to enhance market competitiveness.
Trade with 70% Backtested Accuracy
Analyst Views on HOWL
About HOWL
About the author
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
- Stock Surge: GH Research PLC's stock surged 22.36% to $16.20, gaining $2.96, primarily driven by investor anticipation for a key company update scheduled for January 5, 2026.
- Key Update Announcement: The company will disclose the status of its Investigational New Drug Application (IND) for GH001 and progress on its global pivotal Phase 3 program for treatment-resistant depression (TRD), which is expected to have significant implications for the treatment landscape.
- Investor Interest Spike: The strong investor interest surrounding the upcoming announcement has led to a substantial increase in GH Research's stock price, reflecting heightened market confidence in the biotech sector.
- Positive Market Reaction: Despite no new updates from other biotech firms like Phathom Pharmaceuticals and Forte Biosciences, their stock prices also rose, indicating a broader optimistic sentiment in the biotechnology industry.
Werewolf Reports 30% Response Rate for WTX-124 Monotherapy in Melanoma Patients
- Clinical Data Highlight: WTX-124 demonstrated a 30% overall response rate as a monotherapy in post-ICI advanced melanoma patients, indicating its potential as a best-in-class tolerability drug.
- Efficacy Validation: Initial data from WTX-330 further confirmed its antitumor activity and favorable tolerability, building on the first-in-human trial, showcasing its prospects in challenging tumor types.
- Future Development Plans: The Phase 1/1b trial for WTX-124 is expected to complete in the first half of 2026, with additional data updates planned, potentially requiring further funding to initiate a registration trial.
- Strategic Partnership Opportunities: Werewolf is seeking strategic partners to advance the WTX-124 and WTX-330 INDUKINE programs, leveraging its unique INDUCER T cell engager platform to enhance market competitiveness.
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.
Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.
Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.
General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26
Biotech Stocks Surge: Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a lack of major news.
Modular Medical's Approval: Modular Medical, Inc. saw an 11.51% increase in share price after receiving Institutional Review Board approval for its Pivot insulin delivery system study, which aims to gather critical data on device usability.
Standard BioTools Collaboration: Standard BioTools Inc. advanced 4.90% following a strategic partnership announcement with Molecular Instruments to enhance protein imaging capabilities through next-generation Imaging Mass Cytometry workflows.
Ongoing Investor Optimism: Companies like Werewolf Therapeutics, Cogent Biosciences, and Longeveron also reported gains, reflecting continued investor confidence in their research and development efforts, despite no new corporate updates.
Werewolf Therapeutics Announces FDA Fast Track Designation for WTX-124 in Advanced Melanoma Treatment
Fast Track Designation: Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, aimed at treating patients with advanced cutaneous melanoma after standard immunotherapy, based on promising clinical data.
WTX-124 Therapy: WTX-124 is a conditionally activated IL-2 therapy designed to enhance anti-tumor immune responses while minimizing systemic side effects, currently being evaluated in a Phase 1/1b study alongside pembrolizumab for various advanced solid tumors.
Biotech Stocks Rally in After-Hours Trading: Cassava, Helius, Werewolf, Aytu, and Equillium Drive Late Gains
Cassava Sciences Surge: Cassava Sciences (SAVA) saw a 37.1% increase in after-hours trading, driven by renewed interest in its investigational drug simufilam for TSC-related epilepsy, following positive preclinical data and leadership changes.
Helius Medical Technologies Rebound: Helius Medical Technologies (HSDT) rose 15.67% after announcing a $500 million private placement to pivot towards a Solana-focused treasury vehicle, while also advancing its medical device pipeline.
Werewolf Therapeutics Gains: Werewolf Therapeutics (HOWL) increased by 9.78% in after-hours trading, supported by interest in its INDUKINE platform and upcoming interim data from its lead candidate targeting advanced solid tumors.
Aytu BioPharma and Equillium Updates: Aytu BioPharma (AYTU) rose 7.63% ahead of its fiscal results announcement, while Equillium (EQ) gained 10.34% after securing financing to advance its novel drug EQ504 and progressing its lead candidate in clinical trials.
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
- Stock Surge: GH Research PLC's stock surged 22.36% to $16.20, gaining $2.96, primarily driven by investor anticipation for a key company update scheduled for January 5, 2026.
- Key Update Announcement: The company will disclose the status of its Investigational New Drug Application (IND) for GH001 and progress on its global pivotal Phase 3 program for treatment-resistant depression (TRD), which is expected to have significant implications for the treatment landscape.
- Investor Interest Spike: The strong investor interest surrounding the upcoming announcement has led to a substantial increase in GH Research's stock price, reflecting heightened market confidence in the biotech sector.
- Positive Market Reaction: Despite no new updates from other biotech firms like Phathom Pharmaceuticals and Forte Biosciences, their stock prices also rose, indicating a broader optimistic sentiment in the biotechnology industry.
Werewolf Reports 30% Response Rate for WTX-124 Monotherapy in Melanoma Patients
- Clinical Data Highlight: WTX-124 demonstrated a 30% overall response rate as a monotherapy in post-ICI advanced melanoma patients, indicating its potential as a best-in-class tolerability drug.
- Efficacy Validation: Initial data from WTX-330 further confirmed its antitumor activity and favorable tolerability, building on the first-in-human trial, showcasing its prospects in challenging tumor types.
- Future Development Plans: The Phase 1/1b trial for WTX-124 is expected to complete in the first half of 2026, with additional data updates planned, potentially requiring further funding to initiate a registration trial.
- Strategic Partnership Opportunities: Werewolf is seeking strategic partners to advance the WTX-124 and WTX-330 INDUKINE programs, leveraging its unique INDUCER T cell engager platform to enhance market competitiveness.
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Clene Inc. Gains: Clene Inc. shares rose 8.53% in after-hours trading after announcing an upcoming investor call regarding its CNM-Au8 program for ALS, despite a regular session decline.
Werewolf Therapeutics Update: Werewolf Therapeutics saw a 6.12% increase after hours, likely influenced by investor reactions to its recent presentation at a cancer immunotherapy conference, despite no new news.
Biomea Fusion Presentation: Biomea Fusion's stock climbed 7.31% after hours following its announcement of an upcoming presentation on icovamenib data at a major diabetes and cardiovascular disease congress.
General Market Trends: Other biotech companies like Denali Therapeutics, TScan Therapeutics, and Nyxoah also experienced after-hours gains, reflecting ongoing investor interest and positioning ahead of regulatory milestones and presentations.
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26
Biotech Stocks Surge: Several biotech and life sciences companies experienced significant gains in after-hours trading on November 26, indicating strong investor interest despite a lack of major news.
Modular Medical's Approval: Modular Medical, Inc. saw an 11.51% increase in share price after receiving Institutional Review Board approval for its Pivot insulin delivery system study, which aims to gather critical data on device usability.
Standard BioTools Collaboration: Standard BioTools Inc. advanced 4.90% following a strategic partnership announcement with Molecular Instruments to enhance protein imaging capabilities through next-generation Imaging Mass Cytometry workflows.
Ongoing Investor Optimism: Companies like Werewolf Therapeutics, Cogent Biosciences, and Longeveron also reported gains, reflecting continued investor confidence in their research and development efforts, despite no new corporate updates.
Werewolf Therapeutics Announces FDA Fast Track Designation for WTX-124 in Advanced Melanoma Treatment
Fast Track Designation: Werewolf Therapeutics has received Fast Track Designation from the FDA for WTX-124, aimed at treating patients with advanced cutaneous melanoma after standard immunotherapy, based on promising clinical data.
WTX-124 Therapy: WTX-124 is a conditionally activated IL-2 therapy designed to enhance anti-tumor immune responses while minimizing systemic side effects, currently being evaluated in a Phase 1/1b study alongside pembrolizumab for various advanced solid tumors.
Biotech Stocks Rally in After-Hours Trading: Cassava, Helius, Werewolf, Aytu, and Equillium Drive Late Gains
Cassava Sciences Surge: Cassava Sciences (SAVA) saw a 37.1% increase in after-hours trading, driven by renewed interest in its investigational drug simufilam for TSC-related epilepsy, following positive preclinical data and leadership changes.
Helius Medical Technologies Rebound: Helius Medical Technologies (HSDT) rose 15.67% after announcing a $500 million private placement to pivot towards a Solana-focused treasury vehicle, while also advancing its medical device pipeline.
Werewolf Therapeutics Gains: Werewolf Therapeutics (HOWL) increased by 9.78% in after-hours trading, supported by interest in its INDUKINE platform and upcoming interim data from its lead candidate targeting advanced solid tumors.
Aytu BioPharma and Equillium Updates: Aytu BioPharma (AYTU) rose 7.63% ahead of its fiscal results announcement, while Equillium (EQ) gained 10.34% after securing financing to advance its novel drug EQ504 and progressing its lead candidate in clinical trials.
